Ranibizumab [10 mg/mL solution for intravitreal injection] for first-line treatment of Diabetic Macular Edema (DME), Macular Edema secondary to Retinal Vein Occlusion (ME-RVO), and wet Age-related Macular Degeneration (wAMD)
Pre-Cycle 1 | DrugsHTA Council Recommendation (as of 18 February 2026)
As a final recommendation, the HTA Council recommends the government financing of aRanibizumab [10 mg/mL solution for intravitreal injection] for first-line treatment of Diabetic Macular Edema (DME), Macular Edema secondary to Retinal Vein Occlusion (ME-RVO), and wet Age-related Macular Degeneration (wAMD).
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should ranibizumab [10 mg/mL solution for intravitreal injection] for first-line treatment of Diabetic Macular Edema (DME), Macular Edema secondary to Retinal Vein Occlusion (ME-RVO), and wet Age-related Macular Degeneration (wAMD) be funded by the government?
- Secretary of Health Decision: Approved as of 06 May 2026
Evidence and Relevant Documents